Govt ramps up Remdesivir production

Tribune Web Desk

Updated At : 12:52 PM May 18, 2021 IST

Unlock Exclusive Insights with The Tribune Premium

Take your experience further with Premium access. Thought-provoking Opinions, Expert Analysis, In-depth Insights and other Member Only Benefits

Yearly Premium ₹999 ₹349/Year

Yearly Premium $49 $24.99/Year

New Delhi, May 17

The Union Chemical Ministry on Monday said country’s Remdesivir production capacity has increased from 38 lakh vials per month to nearly 119 lakh vials per month.

“With the efforts of the Centre and the manufacturing companies, the production capacity of the licensed manufacturers has increased unprecedentedly,” the Department of Pharmaceuticals of the Ministry said.

Remdesivir is a patented drug, manufactured in India under voluntary licences granted by Gilead Life Sciences USA, the patent holder, to seven Indian pharmaceutical companies (Cipla, Dr Reddy’s Lab, Hetero, Jubilant Pharma, Mylan, Syngene and Zydus Cadila).

To augment the domestic production capacity, all seven domestic licensed manufacturers of Remdesivir were asked to ramp up production quickly. — TNS

The Tribune, now published from Chandigarh, started publication on February 2, 1881, in Lahore (now in Pakistan). It was started by Sardar Dyal Singh Majithia, a public-spirited philanthropist, and is run by a trust comprising five eminent persons as trustees.

The Tribune, the largest selling English daily in North India, publishes news and views without any bias or prejudice of any kind. Restraint and moderation, rather than agitational language and partisanship, are the hallmarks of the newspaper. It is an independent newspaper in the real sense of the term.

The Tribune has two sister publications, Punjabi Tribune (in Punjabi) and Dainik Tribune (in Hindi).

Remembering Sardar Dyal Singh Majithia

Designed and developed by : SORTD

Unlock Exclusive Insights with The Tribune Premium

Suggested Articles